Search This Blog

Monday, March 16, 2026

Structure Therapeutics reports positive Phase 2 ACCESS II data with oral GLP-1 aleniglipron

 

Structure Therapeutics reports positive Phase 2 ACCESS II data with oral GLP-1 aleniglipron showing ~16% placebo-adjusted weight loss in obesity

  • Phase 2 ACCESS II evaluated aleniglipron over 44 weeks in obesity, including interim open-label extension data.
  • Positive findings support planned Phase 3 initiation of aleniglipron in obesity in 2H 2026.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)